After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
Quigley will start Sept. 30 as the French Big Pharma’s chief scientific officer and global head of research, Sanofi told Fierce Biotech in an emailed statement.
Quigley is replacing Frank Nestle, M.D., who left Sanofi this spring amid a global overhaul of the company’s R&D unit. Nestle, who spent eight years with the pharma, jumped over to Deerfield Management, where he currently serves as a partner on the therapeutics team and CEO of the firm’s therapeutic discovery and development operations.
Quigley will join Sanofi from a San Francisco-based biotech that’s in stealth, according to his LinkedIn profile. He’s currently listed as the company’s co-founder, president and CEO.
The soon-to-be Sanofi leader also previously helmed Therini Bio, an immunotherapy biotech working to develop treatments for neurodegenerative diseases driven by vascular dysfunction.
Before spending the last few years in biotech, Quigley has an even longer track record in Big Pharma, most recently serving as Gilead’s senior vice president of research biology until the summer of 2021. Before that, he clocked in more than four years across various leadership roles at Bristol Myers Squibb and served as a scientific director at Johnson & Johnson’s Janssen arm before that.
Sanofi said Quigley’s mission in his new role would be to “maximize our probability of success through optimal collaborations across our organization and beyond, bringing best-in-class innovation as well as developing and sourcing new industry-leading talent with a commitment to diversity,” according to an internal memo obtained by STAT.
By Gabrielle Masson
Source: fiercebiotech.com
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire obesity biotech Metsera. After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn offer.
French industrial group Anjac Health & Beauty has acquired food supplements supplier PharmaLinea and now comprises 17 complementary companies with R&D and production capacities in health, beauty, personal care, and food supplements.
The big pharma company will pay $221.50 per share in cash to buy Cidara, a US biotech that has developed a platform of drug-Fc conjugates (DFCs). The technology has allowed Cidara to build molecules with prolonged half-life whose efficacy does not require an immune response.
